Αποτελέσματα αναζήτησης - "СИНДРОМ ВОЛЬФА-ПАРКИНСОНА-УАЙТА"

1

Academic Journal

High Comorbidity in Premature Infant: Abdominal Aortic Thrombosis, Wolff-Parkinson-White Syndrome, Secondary Hypothyroidism ; Клинический случай высокой коморбидности у недоношенного ребенка — тромбоз брюшного отдела аорты, синдром Вольфа – Паркинсона – Уайта, приобретенный гипотиреоз

Συγγραφείς: Alena S. Tikhonova, Anastasiya M. Kozlova, Anna A. Tsaturova, А. С. Тихонова, А. М. Козлова, А. А. Цатурова

Πηγή: Pediatric pharmacology; Том 20, № 1 (2023); 59-62 ; Педиатрическая фармакология; Том 20, № 1 (2023); 59-62 ; 2500-3089 ; 1727-5776

Θεματικοί όροι: клинический случай, aortic thrombosis, Wolff-Parkinson-White syndrome, secondary hypothyroidism, children, clinical case, тромбоз аорты, синдром Вольфа – Паркинсона – Уайта, приобретенный гипотиреоз, дети

Περιγραφή αρχείου: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/2268/1464; Бокарев И.Н., Попова Л.В. Современные проблемы тромбозов артерий и вен // Практическая медицина. — 2014. — № 6. — С. 13–17.; Свирин П.В., Румянцев С.А., Ларина Л.Е. и др. Лечение неонатальных тромбозов. Проект клинического протокола // Неонатология: Новости. Мнения. Обучение. — 2013. — № 1. — С. 76–85.; Shaik M, Patel D, Mihir B, et al. Epidemiology, Diagnosis and Management of Neonatal Thrombosis. Blood. 2019;134(Suppl 1):3656. doi: https://doi.org/10.1182/blood-2019-129914; Dieffenbach BV, Nath BD, Tracy ET, Kim HB. Management of symptomatic neonatal aortic thrombosis: When is surgery indicated? J Pediatr Surg Case Rep. 2019;47:101247. doi: https://doi.org/10.1016/j.epsc.2019.101247; Chhabra L, Goyal A, Benham MD. Wolff Parkinson White Syndrome. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.; Джанашия П.Х., Шевченко Н.М., Рыжова Т.В. Роль амиодарона в лечении аритмий // Лечащий врач. — 2006. — № 3. Доступно по: https://www.lvrach.ru/2006/03/4533545. Ссылка активна на 08.02.2023.; Мкртумян А.М., Бирюкова Е.В., Егшатян Л.В. и др. Амиодарон-индуцированный тиреотоксикоз 1 типа: особенности ведения пациентов // Эффективная фармакотерапия. — 2019. — Т. 15. — № 25. — С. 8–11. — doi: https://doi.org/10.33978/2307-3586-2019-15-25-8-11; Стародубова А.В. Амиодарон. Что должен знать практикующий врач // АтмосферА. Новости кардиологии. — 2011. — № 1. — С. 19–25.; Narayana SK, Woods DR, Boos CJ. Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011;2(3):115–126. doi: https://doi.org/10.1177/2042018811398516; Danzi S, Klein I. Amiodarone-induced thyroid dysfunction. J Intensive Care Med. 2015;30(4):179–185. doi: https://doi.org/10.1177/0885066613503278; Лебедева Е.А., Яблонская Ю.А., Булгакова С.В. Амиодарониндуцированный тиреотоксикоз. Современный взгляд на проблему // Клиническая и экспериментальная тиреоидология. — 2017. — Т. 13. — № 2. — С. 31–38. — doi: https://doi.org/10.14341/ket2017231-38; https://www.pedpharma.ru/jour/article/view/2268

Διαθεσιμότητα: https://www.pedpharma.ru/jour/article/view/2268
https://doi.org/10.15690/pf.v20i1.2524

View record from BASE

2

Academic Journal

Hypertrophic cardiomyopathy caused by mutations in the PRKAG2 gene ; Гипертрофическая кардиомиопатия, обусловленная мутациями в гене PRKAG2

Συγγραφείς: I. V. Leontyeva, N. V. Shcherbakova, E. P. Kalachanova, S. A. Thermosesov, V. S. Sukhorukov, И. В. Леонтьева, Н. В. Щербакова, Е. П. Калачанова, С. А. Термосесов, В. С. Сухоруков

Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 67, № 4 (2022); 99-107 ; Российский вестник перинатологии и педиатрии; Том 67, № 4 (2022); 99-107 ; 2500-2228 ; 1027-4065

Θεματικοί όροι: антиаритмическая терапия, PRKAG2, hypertrophic cardiomyopathy, Wolf—Parkinson—White syndrome, radiofrequency ablation, antiarrhythmic therapy, гипертрофическая кардиомиопатия, синдром Вольфа–Паркинсона–Уайта, радиочастотная аблация

Περιγραφή αρχείου: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1681/1269; Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr В. et al. Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1215- 1220. DOI:10.1093/hmg/10.11.1215 (2001); Lopez-Sainz A., Dominguez F., Lopes L.R., Ochoa J.P., Barriales-Villa R., Climent V., et. al. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis J Am Coll Cardiol 2020; 76(2): 186-197. DOI:10.1016/j.jacc.2020.05.029; Porto A.G., Brun F., Severini G.M., Losurdo P., Fabris E., Taylor M.R.G. et al. Clinical Spectrum of PRKAG2 Syndrome. Circ Arrhythm Electrophysiol 2016; 9(1): e003121. DOI:10.1161/CIRCEP.115.003121; Banankhah P., Fishbein G.A., Dota A., Ardehali R. Cardiac manifestations of PRKAG2 mutation. BMC Med Genet 2018; 19(1): 1. DOI:10.1186/s12881-017-0512-6; Gollob M.H., Green M.S., Tang A.S., Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002;17: 229-234. DOI:10.1097/00001573-200205000-00004; Thevenon J., Laurent G., Ader F., Laforêt P., Klug D., Duva Pentiah A. et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations. Europace 2017; 19: 651-659. DOI:10.1093/europace/euw067; Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P., Perez-Atayde A.R. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362-372. DOI:10.1056/NEJMoa033349; Fabris E., Brun F., Porto A.G., Losurdo P., Vitali Serdoz L., Zecchin M. et al. Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome. J Am Coll Cardiol 2013; 62(9): e17. DOI:10.1016/j.jacc.2013.02.099; Aggarwal V., Dobrolet N., Fishberger S., Zablah J., Jayakar P., Ammous Z. PRKAG2 mutation: An easily missed cardiac specific non-lysosomal glycogenosis. Ann Pediatr Cardiol 2015; 8(2): 153-156. DOI:10.4103/0974-2069.154149; van der Steld L.P., Campuzano O., Pérez-Serra A., Moura de Barros Zamorano M., Sousa Matos S., Brugada R. Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family. Am J Case Rep 2017; 18: 766-776. DOI:10.12659/AJCR.904613; Hu J., Tang B., Wang J., Huang K., Wang Y., Lu S. et al. Familial Atrial Enlargement, Conduction Disorder and Symmetric Cardiac Hypertrophy Are Early Signs of PRKAG2 R302Q. Curr Med Sci 2020; 40(3): 486-492. DOI:10.1007/s11596-020-2207-z

Διαθεσιμότητα: https://www.ped-perinatology.ru/jour/article/view/1681
https://doi.org/10.21508/1027-4065-2022-67-4-99-107

View record from BASE

3

Academic Journal

PRKAG2-associated hypertrophic cardiomyopathy ; PRKAG2-ассоциированная гипертрофическая кардиомиопатия

Συγγραφείς: I. V. Leontyeva, И. В. Леонтьева

Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 67, № 3 (2022); 111-116 ; Российский вестник перинатологии и педиатрии; Том 67, № 3 (2022); 111-116 ; 2500-2228 ; 1027-4065

Θεματικοί όροι: сердечная недостаточность, hypertrophic cardiomyopathy, PRKAG2-syndrome, Wolff-Parkinson-White syndrome glycogenosis, heart failure, гипертрофическая кардиомиопатия, PRKAG2-синдром, синдром Вольфа–Паркинсона–Уайта, гликогеноз

Περιγραφή αρχείου: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1661/1253; Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014; 35: 2733–2779. DOI:10.1093/eurheartj/ehu284; Maron B., Rowin E., Casey S., Lesser J., Garberich R., McGriff D.M., Maron M.S. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation 2016; 133(1): 62–73. DOI:10.1161/circulationaha.115.01763; Lipshultz S.E., Orav E.J., Wilkinson J. D., Towbin J.A., Messere J.E., Lowe A.M. et al. Risk stratification at the time of diagnosis for children with hypertrophic cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry Study Group. Lancet 2013; 382(9908): 1889–1897. DOI:10.1016/S0140–6736(13)61685–2; Леонтьева И.В. Дифференциальная диагностика гипертрофической кардиомиопатии Российский вестник перинатологии и педиатрии 2017; 62(3): 20–31.; Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P., Perez-Atayde A.R. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362–372. DOI:10.1056/NEJMoa033349; Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr В., Salmon А. et al. Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1215–1220. DOI:10.1093/hmg/10.11.1215; Lopez-Sainz A., Dominguez F., Lopes L.R., Ochoa J.P., Barriales-Villa R., Climent V. et al. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis J Am Coll Cardiol 2020; 76(2): 186–197. DOI:10.1016/j.jacc.2020.05.029; Murphy R.T., Mogensen J., McGarry K., Bahl A., Evans A., Osman E. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff–Parkinson–White syndrome: natural history. J Am Coll Cardiol 2005; 45: 922–930. DOI:10.1016/j.jacc.2004.11.053; Porto A.G., Brun F., Severini G.M., Losurdo P., Fabris E., Taylor M.R.G. et al. Clinical Spectrum of PRKAG2 Syndrome. Circ Arrhythm Electrophysiol 2016; 9: e003121. DOI:10.1161/CIRCEP.115.003121; MacRae С.A., Ghaisas N., Kass S., Donnell S., Basson C., Watkins H. et al. Familial Hypertrophic cardiomyopathy with Wolff–Parkinson–White syndrome maps to a locus on chromosome 7q3 l. Clin Invest 1995; 96(3): 1216–1220. DOI:10.1172/JCI118154; Yang K.Q., Lu C.X., Zhang Y., Yang Y.K., Li J.C., Lan T. et al. A novel PRKAG2 mutation in a Chinese family with cardiac hypertrophy and ventricular pre-excitation. Sci Rep 2017; 7(1): 2407. DOI:10.1038/s41598-017-02455-z; Lang T., Yu L., Tu Q., Jiang J., Chen, Z., Xin Y. et al. Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant Ȗ2 subunit of 5 -AMP-activated protein kinase, to human chromosome 7q36. Genomics 2000; 70: 258–263. DOI:10.1006/geno.2000.6376; Merante F., Tein I., Benson L., Robinson B.H. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA (glycine) gene. Am J Hum Genet 1994; 55: 437–446.; Puccio H., Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000; 9: 887–892. DOI:10.1093/hmg/9.6.887; Bonnet D., Martin D., De Lonlay P., Villain E., Jouvet P., Rabier D. et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999; 100: 2248–2253. DOI:10.1161/01.cir.100.22.2248; Arad M., Moskowitz I.P., Patel V.V., Ahmad F., PerezAtayde A.R., Sawyer D.B. et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff–Parkinson–white syndrome in glycogen storage cardiomyopathy. Circulation 2003; 107: 2850–2856. DOI:10.1161/01.CIR.0000075270.13497.2B; Banankhah P., Fishbein G.A., Dota A., Ardehali R. Cardiac manifestations of PRKAG2 mutation. BMC Med Genet 2018; 19(1): 1. DOI:10.1186/s12881-017-0512-6; Gollob M.H., Green M.S., Tang A.S., Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002; 17: 229–234. DOI:10.1097/00001573-200205000-00004; Sternick E.B., Oliva A., Gerken L.M., Hong K., Santana O., Brugada P. et al. Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation. Hear Rhythm 2011; 8: 58–64. DOI:10.1016/j.hrthm.2010.09.081; Wolf C.M., Arad M., Ahmad F., Sanbe A., Bernstein S.A., Toka O. et al. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation 2008; 117: 144–154. DOI:10.1161/CIRCULATIONAHA.107.726752; Gollob M. H., Seger J. J., Gollob T. N., Tapscott Т., Gonzales О., Bachinski L., Roberts R. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104: 3030–3033. DOI:10.1161/hc5001.102111; Thevenon J., Laurent G., Ader F., Laforêt P., Klug D., Duva Pentiah A. et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations. Europace 2017; 19: 651–659. DOI:10.1093/europace/euw067; van der Steld L.P., Campuzano O., Pérez-Serra A., Moura de Barros Zamorano M., Sousa Matos S., Brugada R. Wolff–Parkinson–White Syndrome with Ventricular Hypertrophy in a Brazilian Family. Am J Case Rep 2017; 18: 766–776. DOI:10.12659/AJCR.904613; Sternick E.B., Oliva A., Magalhaes L.P., Gerken L.M., Hong K., Santana O. et al. Familial pseudo-Wolff–Parkinson–White syndrome. J Cardiovasc Electrophysiol 2006; 17: 724–732 DOI:10.1111/j.1540-8167.2006.00485; Burwinkel B., Scott J.W., Buhrer C., van Landeghem F.K., Cox G.F., Wilson C.J. et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 2005; 76: 1034–1049. DOI:10.1086/430840; Zhang L.P., Hui B., Gao B.R. High risk of sudden death associated with a PRKAG2-related familial Wolff–Parkinson–White syndrome. J Electrocardiol 2011; 44: 483–486. DOI:10.1016/j.jelectrocard. 2010.02.009; Fabris E., Brun F., Porto A.G., Losurdo P., Vitali Serdoz L., Zecchin M. et al. Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome. J Am Coll Cardiol 2013; 62(9): e17. DOI:10.1016/j.jacc.2013.02.099; Lorenzini M., Anastasiou Z., O’Mahony C., Gimeno J.R., Monserrat L., Anastasakis А. et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol 2020; 5: 73–80. DOI:10.1001/jamacardio.2019.4534; Гандаева Л.А., Кондакова О.Б., Басаргина Е.Н., Пушков А.А., Колоскова Н.Н., Жарова О.П. и др. Гликогеновая болезнь сердца — синдром PRKAG2. Российский вестник перинатологии и педиатрии 2022; 67(2): 133–137.; Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B. Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD (NCT03882437). https://ichgcp.net/ru/clinical-trials-registry/NCT03882437 / Ссылка активна на 16.04.2022

Διαθεσιμότητα: https://www.ped-perinatology.ru/jour/article/view/1661
https://doi.org/10.21508/1027-4065-2022-67-3-111-116

View record from BASE

4

Report

ВЕДЕНИЕ СЛОЖНЫХ НАРУШЕНИЙ РИТМА У ПАЦИЕНТКИ С НЕКОМПАКТНЫМ МИОКАРДОМ (случай из практики)

Θεματικοί όροι: электрокардиостимулятор, некомпактный миокард, non-compact myocardium, Wolff-Parkinson-White syndrome, синдром Вольфа-Паркинсона-Уайта, брадикардия, bradycardia, pacemaker

5

Academic Journal

ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: PRACTICAL ASPECTS AND DISCUSSION ISSUES OF RATIONAL PHARMACOTHERAPY ; ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: ПРАКТИЧЕСКИЕ АСПЕКТЫ И ДИСКУССИОННЫЕ ВОПРОСЫ РАЦИОНАЛЬНОЙ ФАРМАКОТЕРАПИИ

Συγγραφείς: Yu. Bunin А., S. Miklishanskaya V., Ю. Бунин А., С. Миклишанская В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 13, No 6 (2017); 856-862 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 6 (2017); 856-862 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-6

Θεματικοί όροι: atrial fibrillation, chronic heart failure, anticoagulants, antiarrhythmics, rate control, rhythm control, Wolff-Parkinson-White syndrome, фибрилляция предсердий, хроническая сердечная недостаточность, антикоагулянты, антиаритмические препараты, контроль частоты, контроль ритма, синдром Вольфа-Паркинсона-Уайта

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1579/1580; ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442. doi:10.1093/eurheartj/ehn309.; Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol. 2003;93:2D-8D. doi:10.1016/S0002-9149(02)03373-8.; Schneider M.P., Hua T.A., Bohm M. et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55:2299-307. doi:10.1016/j.jacc.2010.01.043.; Healey J.S., Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9. doi:10.1016/j.jacc.2004.11.070.; 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration wit EACTS. Eur Heart J. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210; Swedberg K., Zannad F., McMurray J.J. et al. Eplerinone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF study. J Am Coll Cardiol. 2012;59:1598-603. doi:10.1016/j.jacc.2011.11.063.; Martin R.R., Pogoryelova O., Koref M.S. et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart. 2014;100:1506-10. doi:10.1136/heartjnl2014-305482.; Mc Murray J.J., Packer M., Desai A.S. et al. Paradigm-HF investigators and committees. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi:10.1056/NEJMoa1409077.; 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130:e199–e267. https://doi.org/10.1161/CIR.0000000000000041; Hess P.L., Jackson K.P., Hasselblad V. Al-Khatib S.M. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A Systematic Review and Meta-Analysis. Curr Cardiol Rep. 2013;15(2):330. doi:10.1007/s11886-012-0330-6; 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-200. doi:10.1093/eurheartj/ehw128.; Roskell N.S., Samuel M., Noack H. et al. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013;15:787-97. doi:10.1093/europace/eut001.; Update European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-51. doi:10.1093/europace/euv309.; Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY steering committee and investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Gard J. et al. ROCKET-AF investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638.; Granger C.B., Alexander J.H., Mc Murray J.J. et al. ARISTOTLE committees and investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NEJMoa1107039.; Holmes D.R., Doshi S.K., Kar S. et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65:261423. doi:10.4330/wjc.v9.i2.139.; Bunin Yu.A., Miklishanskaya S.V. Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. Ration Pharmacother Cardiol. 2016;12(4):465-70. (In Russ.) [Бунин Ю.А., Миклишанская С.В. Клиническое значение новых оральных антикоагулянтов в профилактике тромбоэмболических осложнений у больных с фибрилляцией предсердий: не все мечты сбываются. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):465-470]. doi:10.20996/1819-6446-201612-4-465-470.; Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;385:2667-77. doi:10.1056/NEJMoa0708789.; Van Gelder I.C., Groenveld H.F., Crijns H.J. et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. doi:10.1056/NEJMoa1001337.; Kotecha D., Holmes J., Krum H. et al. Beta-blockers in heart failure collaborative group. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data metaanalysis. Lancet. 2014;384:2235-43. doi:10.1016/S0140-6736(14)61373-8.; Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opion Cardiol. 2000;15:4153.; Bardy G.H., Lee K.L., Mark D.B. et al. Amiadarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. doi:10.1056/NEJMoa043399; https://www.rpcardio.com/jour/article/view/1579

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/1579
https://doi.org/10.20996/1819-6446-2017-13-6-856-862

View record from BASE

6

Academic Journal

PARAHISIAN MAHAIM FIBER ; ПАРАГИСИАЛЬНЫЙ ТРАКТ МАХАЙМА

Συγγραφείς: S. E. MAMCHUR, E. A. KHOMENKO, N. S. BOKHAN, M. P. ROMANOVA, T. Yu. CHICHKOVA, С. Е. МАМЧУР, Е. А. ХОМЕНКО, Н. С. БОХАН, М. П. РОМАНОВА, Т. Ю. ЧИЧКОВА

Πηγή: Complex Issues of Cardiovascular Diseases; № 1 (2017); 153-157 ; Комплексные проблемы сердечно-сосудистых заболеваний; № 1 (2017); 153-157 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2017-1

Θεματικοί όροι: синдром Вольфа-Паркинсона-Уайта, Wolff-Parkinson-White syndrome

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/275/242; Ревишвили А.Ш., Давтян К.В., Лабарткава Е.З. Современное представление о трактах Махайма, электрофизиологические свойства и результаты интервенционного метода лечения. Вестник аритмологии. 2007; 47: 15-22. Revishvili A.Sh., Davtjan K.V.; Labartkava E.Z.Sovremennoe predstavle-nie o traktah Mahajma, jelektrofiziologicheskie svojstva i rezul’taty intervencion-nogo metoda lechenija. Vestnik aritmologii. 2007; 47: 15- 22. [In Russ.]; Ablation of right free wall and atriofascicular accessory pathways G. To-massoni [et al.] Interventional electrophysiology. 2nd ed. ed. I. Singer. Phila-delphia: Lippincott Williams & Wilkins. 2001; 193-219.; ACC/AHA/ESC guidelines for the management of patients with supraventric-ular arrhythmias – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) C. Blomstrom- Lundqvist [et al.]. Circu-lation. 2003; 108: 1871–1909.; Kalbfleisch S., Bowman K., Augostini R. A single Mahaim fiber causing both antidromic and orthodromic reciprocating tachycardia J. Cardiovasc. Electro-physiol. 2008; 19(7): 740- 742.; Mahaim I., Bennett A. Nouvelle recherches sur les connexions superieures de la branche gauche du faiscesu de His-Tawara avec cloison interventriculaire Cardiologia. 1938; 1: 61-76.; Klein G. J., Guiraudon G.M., Kerr C.R., Sharma A.D., Yee R., Szabo T. et al. «Nodoventricular» accessory pathway: evidence for a distinct accessory atrio-ventricular pathway with AV node-like properties. J.A.C.C. 1988; 11: 1035- 1040.; Leitch J., Klein G.J., Yee R., Murdock C. New concepts of nodoventricular accessory pathways. J. Clin. Electrophysiol. 1990; 1: 220-230.; Hoffmayer K.S., Lee B.K., Vedantham V., Bhimani A.A., Cakulev I.T., Mackall J.A. et al. Variable clinical features and ablation of manifest nodofascicular/ventricular pathways. Circ. Arrhythm. Electrophysiol. 2015; 8(1): 117-127. doi:10.1161/CIRCEP.114.001924.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/275
https://doi.org/10.17802/2306-1278-2017-1-153-157

View record from BASE

7

Academic Journal

ПАРАГИСИАЛЬНЫЙ ТРАКТ МАХАЙМА

Συγγραφείς: Сергей Евгеньевич Мамчур, Егор Александрович Хоменко, Никита Сергеевич Бохан, Мария Петровна Романова, Татьяна Юрьевна Чичкова

Πηγή: Complex Issues of Cardiovascular Diseases; № 1 (2016) ; Комплексные проблемы сердечно-сосудистых заболеваний; № 1 (2016) ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2016-1

Θεματικοί όροι: синдром Вольфа-Паркинсона-Уайта

Relation: https://www.nii-kpssz.com/jour/article/downloadSuppFile/128/1; Ревишвили А.Ш., Давтян К.В., Лабарткава Е.З. Современное представление о трактах Махайма, электрофизиологические свойства и результаты интервенционного метода ле-чения // Вестник аритмологии 2007. №47. С. 15-22.; Ablation of right free wall and atriofascicular accessory pathways / G. Tomassoni [et al.] // Interventional electrophysiology. 2nd ed. / ed. I. Singer. Philadelphia: Lippincott Williams & Wilkins, 2001. P. 193-219.; ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology/American Heart Associa-tion Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) / C. Blomstrom-Lundqvist [et al.] // Circulation 2003. Vol. 108. P. 1871–1909.; Kalbfleisch S., Bowman K., Augostini R. A single Mahaim fiber causing both antidromic and orthodromic reciprocating tachycardia // J. Cardiovasc. Electrophysiol. 2008. Vol. 19(7). P. 740-742.; Mahaim I., Bennett A. Nouvelle recherches sur les connexions superieures de la branche gauche du faiscesu de His-Tawara avec cloison interventriculaire // Cardiologia 1938. Vol. 1. P. 61-76.; “Nodoventricular” accessory pathway: evidence for a distinct accessory atrioventricular path-way with AV node-like properties / G.J. Klein [et al.] // J.A.C.C. 1988. Vol. 11. P. 1035-1040.; New concepts of nodoventricular accessory pathways / J.W. Leitch [et al.] // J. Clin. Electro-physiol. 1990. Vol. 1. P. 220-230.; Variable clinical features and ablation of manifest nodofascicular/ventricular pathways / K.S. Hoffmayer [et al.] // Circ. Arrhythm. Electrophysiol. 2015. Vol. 8(1). P. 117-127.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/128

View record from BASE

8

Academic Journal

КАТЕТЕРНАЯ АБЛАЦИЯ ПРИ СИНДРОМЕ ВОЛЬФА-ПАРКИНСОНА-УАЙТА НА ФОНЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

Συγγραφείς: Хоменко Егор Александрович, Сергей Евгеньевич Мамчур, Никита Сергеевич Бохан, Мария Петровна Романова, Татьяна Юрьевна Чичкова

Πηγή: Complex Issues of Cardiovascular Diseases; № 1 (2016) ; Комплексные проблемы сердечно-сосудистых заболеваний; № 1 (2016) ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2016-1

Θεματικοί όροι: синдром Вольфа-Паркинсона-Уайта, катетерная аблация

Relation: https://www.nii-kpssz.com/jour/article/downloadSuppFile/167/21; Steinbeck G. Should radiofrequency current ablation be performed in asymptomatic patients with the Wolff-Parkinson-White syndrome? Pacing Clin Electrophysiol. 1993;16(3 Pt 2):649-652.; Wellens HJ. When to Perform Catheter Ablation in Asymptomatic Patients With a Wolff-Parkinson-White Electrocardiogram. Circulation 2005;112:2201-2216.; Синдром Вольфа-Паркинсона-Уайта: клиника, диагностика, лечение. М.: ИД «Медпрак-тика-М», 2014 – 160 с.; Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circula-tion 1985;72(1):161-169.; Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrilla-tion in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301(20):1080-1085.; Fitzsimmons PJ, McWhirter PD, Peterson DW, Kruyer WB. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. Am Heart J. 2001;142(3):530-536.; Klein GJ, Prystowsky EN, Yee R, Sharma AD, Laupacis A. Asymptomatic Wolff-Parkinson-White. Should we intervene? Circulation 1989;80(6):1902-1905.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/167

View record from BASE

9

Academic Journal

SAFETY OF AMIODARONE USAGE IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION ; К ВОПРОСУ О БЕЗОПАСНОСТИ ВВЕДЕНИЯ АМИОДАРОНА ПАЦИЕНТАМ С СИНДРОМОМ ВОЛЬФА-ПАРКИНСОНА-УАЙТА И ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

Συγγραφείς: D. Kuzhel A., G. Matyushin V., E. Savchenko A., Д. Кужель А., Г. Матюшин В., Е. Савченко А.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 6, No 3 (2010); 359-362 ; Рациональная Фармакотерапия в Кардиологии; Vol 6, No 3 (2010); 359-362 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2010-6-3

Θεματικοί όροι: amiodarone, atrial fibrillation, Wolff-Parkinson-White syndrome, ventricular fibrillation, амиодарон, фибрилляция предсердий, синдром Вольфа-Паркинсона-Уайта, фибрилляция желудочков

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/879/912; Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354.; Roden D.M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000;84(3):339-46.; Zimetbaum P. Amiodarone for Atrial Fibrillation. N Engl J Med 2007;356(9):935- 41.; Blomström-Lundqvist C., Scheinman M.M., Aliot E.M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108(15):1871-909.; Basson C.T. A molecular basis for Wolff–Parkinson–White syndrome. N EnglJ Med 2001;344(24):1861-4.; Gollob M.H., Green M.S., Tang A.S-L. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.; Basavarajaiah S., Shah A., Sharma S. Sudden cardiac death in young athletes.Heart 2007;93(3):287-9.; Wren C. Sudden death in children and adolescents. Heart 2002;88(4):426-31.; Диагностика и лечение фибрилляции предсердий. Рекомендации комитета экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2005;4(4 Приложение 1):1-30.; Boriani G., Biffi M., Frabetti L. et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131(6):1214-6.; Feld G.K., Nademanee K., Stevenson W. et al. Clinical and electrophysiologic effects of amiodarone in patients with atrialfibrillation complicating theWolff-Parkinson-White syndrome. Am Heart J 1988;115(1 Pt 1):102-7.; Kappenberger L.J., Fromer M.A., Steinbrunn W., Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984;54(3):330- 5.; Perticone F., Cuda G., Spadea F. et al. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment. Clin Cardiol 1987;10(8):477-80.; Schützenberger W., Leisch F., Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol 1987;16(1):93-5.; Tijunelis M.A.,Herbert M.E. Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM 2005;7(4):262-5.; Vitale P., De Stefano R., Auricchio A. Possible danger of rapid intravenous amiodarone in re-entry tachycardia in subjects with Wolff-Parkinson-White syndrome (in Italian). G Ital Cardiol 1986;16(11):969-74.; https://www.rpcardio.com/jour/article/view/879

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/879
https://doi.org/10.20996/1819-6446-2010-6-3-359-362

View record from BASE

10

Academic Journal

THE WOLFF – PARKINSON – WH ITE SYNDROME OF HEART ALLOGRAFT AND CATHETER ABLATION OF ACCESSORY PATHW AY AFTER ORTHOTOPIC HEART TRANSPLANTATION ; СИНДРОМ ВОЛЬФ А – ПАРКИНСОНА – УАЙТА ДОНОРСКОГО СЕРДЦА И КАТЕТЕРНАЯ АБЛАЦИЯ ПУЧКА КЕНТА ПОСЛЕ ОРТОТОПИЧЕСКОЙ ТРАНСПЛАНТАЦИИ СЕРДЦА

Συγγραφείς: S. E. Mamchur, E. S. Malyshenko, E. A. Khomenko, N. S. Bokhan, С. Е. Мамчур, Е. С. Малышенко, Е. А. Хоменко, Н. С. Бохан

Πηγή: Complex Issues of Cardiovascular Diseases; № 4 (2014); 33-37 ; Комплексные проблемы сердечно-сосудистых заболеваний; № 4 (2014); 33-37 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2014-4

Θεματικοί όροι: катетерная аблация, Wolff – Parkinson – White syndrome, catheter ablation, синдром Вольфа – Паркинсона – Уайта

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/80/83; Курилин М. Ю., Мамчур С. Е . Современное состояние вопроса о катетерной аблации идиопатических эктопических желудочковых аритмий. Ч. 1 // Комплексные проблемы сердечно-сосудистых заболеваний. 2013. № 4. С. 94–101.; Трансплантация сердца. Национальные клинические рекомендации / С. В. Готье [и др.] // Общероссийская общественная рекомендация трансплантологов «Российское трансплантологическое общество». 2013. 92 с.; Direct current catheter ablation of an accessory pathway in a recipient with refractory reciprocal tachycardia / P. Gallay [et al.] // J. Heart Lung Transplant. 1992. Vol. 11. P. 442–445.; Fournet D., Zimmermann M., Campanini C. Atrial tachycardia with recipient-to-donor atrioatrial conduction and isthmusdependent donor atrial flutter in a patient after orthotopic heart transplantation. Successful treatment by radiofrequency catheter ablation // J. Heart Lung Transplant. 2002. Vol. 21. P. 923–927.; Interatrial conduction of atrial tachycardia in heart transplant recipients: potential pathophysiology / D. Birnie [et al.] // J. Heart Lung Transplant. 2000. Vol. 19. P. 1007–1010.; Magnano A. R., Garan H. Catheter ablation of supraventricular tachycardia in the transplanted heart: a case series and literature review // Pacing Clin. Electrophysiol. 2003. Vol. 26. P. 1878–1886.; Radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia after orthotopic heart transplantation / F. A. Padder [et al.] // J. Interv. Card. Electrophysiol. 1999. Vol. 3. P. 283–285.; Radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia in a patient with orthotopic heart transplantation by bicaval anastomosis / L. Rodriguez de Armas [et al.] // J. Interv Card. Electrophysiol. 2006. Vol. 15. P. 171–174.; Radiofrequency ablation of a supraventricular tachycardia due to interatrial conduction from the recipient to donor atria in an orthotopic heart transplant recipient / S. A. Rothman [et al.] // J. Cardiovasc. Electrophysiol. 1995. Vol. 6. P. 544–550.; Sharma P. P., Marcus F. I. Radiofrequency ablation of an accessory pathway years after heart transplant: a case report // J. Heart Lung Transplant. 1999. Vol. 18. P. 792–795.; Strohmer B., Chen P. S., Hwang C. Radiofrequency ablation of focal atrial tachycardia and atrioatrial conduction from recipient to donor after orthotopic heart transplantation // J. Cardiovasc. Electrophysiol. 2000. Vol. 11. P. 1165–1169.; Supraventricular Tachycardia After Orthotopic Cardiac Transplantation / M. Vaseghi [et al.] // J. Am. Coll. Cardiol. 2008. Vol. 51. P. 2241–2249.; The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients / M. R. Costanzo [et al.] // J. Heart Lung Transplant. 2010. Vol. 29(8). P. 914–956.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/80
https://doi.org/10.17802/2306-1278-2014-4-33-37

View record from BASE

11

Academic Journal